PIACENTINI, Federico
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.027
EU - Europa 15.636
AS - Asia 13.273
SA - Sud America 1.871
Continente sconosciuto - Info sul continente non disponibili 439
AF - Africa 373
OC - Oceania 78
Totale 60.697
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.137
IT - Italia 5.423
SG - Singapore 3.908
CN - Cina 3.215
GB - Regno Unito 2.590
IE - Irlanda 2.200
HK - Hong Kong 1.503
VN - Vietnam 1.400
BR - Brasile 1.333
DE - Germania 1.190
SE - Svezia 1.027
BD - Bangladesh 800
FR - Francia 575
FI - Finlandia 541
RU - Federazione Russa 517
CA - Canada 442
UA - Ucraina 404
IN - India 400
KR - Corea 367
ID - Indonesia 298
TR - Turchia 291
NL - Olanda 223
BG - Bulgaria 179
AR - Argentina 171
JP - Giappone 164
TW - Taiwan 146
MX - Messico 143
IQ - Iraq 120
ES - Italia 116
PL - Polonia 106
CO - Colombia 87
LT - Lituania 87
ZA - Sudafrica 81
PK - Pakistan 79
CL - Cile 78
AU - Australia 74
BE - Belgio 67
MY - Malesia 67
EC - Ecuador 65
VE - Venezuela 63
AE - Emirati Arabi Uniti 62
EG - Egitto 59
AT - Austria 53
SA - Arabia Saudita 47
CR - Costa Rica 45
CZ - Repubblica Ceca 45
PH - Filippine 45
IR - Iran 43
MA - Marocco 39
JO - Giordania 38
IL - Israele 36
KE - Kenya 35
PR - Porto Rico 34
TH - Thailandia 33
JM - Giamaica 32
CH - Svizzera 30
HN - Honduras 30
NP - Nepal 30
PY - Paraguay 29
RO - Romania 29
TT - Trinidad e Tobago 28
UZ - Uzbekistan 28
SV - El Salvador 26
AL - Albania 25
MD - Moldavia 25
TN - Tunisia 23
AZ - Azerbaigian 22
DZ - Algeria 21
DO - Repubblica Dominicana 20
GR - Grecia 20
CW - ???statistics.table.value.countryCode.CW??? 19
GP - Guadalupe 19
HU - Ungheria 19
NG - Nigeria 18
NI - Nicaragua 18
PE - Perù 18
PT - Portogallo 18
ET - Etiopia 17
EU - Europa 17
DK - Danimarca 16
LB - Libano 15
BO - Bolivia 14
GT - Guatemala 14
RS - Serbia 14
SI - Slovenia 14
SY - Repubblica araba siriana 14
MK - Macedonia 13
SC - Seychelles 12
CI - Costa d'Avorio 11
LV - Lettonia 11
OM - Oman 11
UY - Uruguay 11
BH - Bahrain 10
KZ - Kazakistan 10
PA - Panama 10
AO - Angola 9
BY - Bielorussia 9
SK - Slovacchia (Repubblica Slovacca) 9
BB - Barbados 8
CY - Cipro 8
Totale 60.115
Salva come PNG Salva come JPEG
Città #
Ashburn 3.630
Singapore 2.611
Santa Clara 2.580
Dublin 2.189
Fairfield 1.752
San Jose 1.609
Hong Kong 1.446
Chandler 1.433
Southend 1.325
Council Bluffs 1.281
Woodbridge 1.016
Houston 816
Beijing 769
Seattle 741
Dearborn 736
Nyköping 668
Ann Arbor 667
Hefei 644
Wilmington 627
Jacksonville 614
Dallas 556
New York 549
Cambridge 536
London 525
Milan 523
Los Angeles 488
Ho Chi Minh City 441
Helsinki 402
Rome 372
The Dalles 369
Modena 344
Hanoi 312
Seoul 305
Chicago 300
Jakarta 229
Munich 209
Shanghai 207
Bologna 200
Lauterbourg 197
San Diego 187
Columbus 186
Princeton 180
Sofia 169
Boardman 163
Buffalo 163
Moscow 158
Eugene 141
São Paulo 140
Izmir 132
Frankfurt am Main 120
Naples 115
Orem 113
Dong Ket 112
Fremont 107
Tokyo 107
Redwood City 106
Phoenix 98
Toronto 95
Brooklyn 83
Florence 83
Salt Lake City 81
Bremen 77
Warsaw 75
Atlanta 74
Turin 72
Guangzhou 70
Falls Church 67
Reggio Emilia 66
Montreal 65
Genoa 63
Bari 62
Denver 61
Tampa 61
Taichung 58
Redondo Beach 57
Chennai 55
Da Nang 55
Parma 55
Palermo 53
Brussels 50
Mumbai 50
Amsterdam 49
Baghdad 49
Haiphong 49
North Bergen 48
Miami 47
Norwalk 46
Nuremberg 44
Ottawa 44
Springfield 44
Turku 44
Elk Grove Village 42
Mexico City 41
Rio de Janeiro 41
San Francisco 41
Santiago 41
Newark 40
Philadelphia 39
Verona 39
Boston 38
Totale 39.129
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.191
Oxford Manuale di Medicina Clinica 774
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 656
Abemaciclib: eventi avversi e riduzione di dose. 586
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 515
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer 505
RISULTATI DELLA RADIOTERAPIA PANENCEFALICA (WBRT) NELLE METASTASI CEREBRALI DA CARCINOMA DELLA MAMMELLA: STUDIO RETROSPETTIVO SUL RUOLO PROGNOSTICO DEI FATTORI BIOLOGICI 491
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 481
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 463
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 454
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 449
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 448
GD2 expression in breast cancer. 448
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 443
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 440
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial 434
Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients 428
Survival analysis of the prospective randomized Cher-Lob study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 427
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 424
Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going 419
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 419
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 414
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 411
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 409
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 406
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 406
Impact of body composition parameters on tumor response to neoadjuvant chemotherapy in operable breast cancer patients. 405
Clinical and molecular analysis of long-term HER2 positive metastatic breast cancer survivors. 399
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 399
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience 397
Clinical Prognosticators in Patients Treated with CDK 4/6 Inhibitors for Hormone Receptors Positive Advanced Breast Cancer 390
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 388
Molecular Profile, as detected with Mass-Array Spectrometry (Sequenom platform), in primary and metastatic breast carcinoma treated with Exemestane + Everolimus 386
Axillary Ectopic Carcinoma of the Breast. Report of Two Cases with Different Clinical Presentation and Review of the Literature. 386
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial 384
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 384
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 383
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 382
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 379
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 377
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 375
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 371
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 370
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 367
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer. 364
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 359
Tumor Stroma Manipulation By MSC 359
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 353
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 352
Post-surgical pyoderma gangrenosum of the breast: needs for early diagnosis and right therapy. 350
Achievements and unmet needs in the management of advanced ovarian cancer 349
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 349
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 347
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 347
Predictors of HER2 gene amplification in immunohistochemistry score 2+ Early Breast Cancer according to 2018 ASCO/CAP guidelines: a single institution analysis. 343
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 342
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 341
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 339
Modulation of Mutational Landscape in HER2-Positive Breast Cancer after Neoadjuvant Chemotherapy 338
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 336
Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience. 333
Biomarker expression and survival after primary chemotherapy for breast cancer. 333
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 333
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 332
Molecular profile in primary and metastatic breast cancer treated with Exemestane and Everolimus. 331
Metronomic Capecitabine Effectively Blocks Leptomeningeal Carcinomatosis From Breast Cancer: A Case Report and Literature Review. 331
Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid. 331
Impact of time to surgery after neoadjuvant chemotherapy in patients with operable breast cancer. 330
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status 329
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 329
Immune characterization of breast cancer metastases: prognostic implications. 327
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 323
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 320
Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer 318
Primary pulmonary cancer colliding with metastatic breast carcinoma: hitherto unreported cases of cancer-to-cancer metastasis focusing on clinical implications 317
Prognostic significance of germline BRCA mutations in patients with HER2-positive breast cancer. Epidemiological analysis in primary BRCA screens 317
Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy. 316
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer 314
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 314
Breast Location for De Novo Extramedullary Myeloid Sarcoma 312
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 307
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 305
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 304
Preoperative Carboplatin–Paclitaxel–Bevacizumab in Triple-Negative Breast Cancer: Final Results of the Phase II Ca.Pa.Be Study 303
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 302
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 300
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer 299
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 299
Impact of anaemia on tumor response to neoadjuvant chemotherapy in breast cancer patients . 296
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 295
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 294
Primary treatment strategy in elderly patients with hormone receptor positive early breast cancer: is breast cancer surgery. 294
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 294
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 293
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 290
Adjuvant exemestane or tamoxifen plus ovarian suppression in premenopausal women: single institution analysis 289
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 288
Preoperative carboplatin-paclitaxel-bevacizumab in triple negative breast cancer: Final results of the phase II CA.Pa.Be study 286
Prognostic impact of estrogen receptor (ER) level changes during progression for patients with both ER-positive (ER+) primary breast cancer and paired recurrence 284
Differential gene expression patterns in HER2 positive metastatic breast cancer patients according to hormone receptor status. 284
Totale 37.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 210.600
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 210.600
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.416 0 0 0 0 124 264 152 199 366 301 594 416
2022/20236.486 494 585 344 417 410 514 111 388 2.573 114 325 211
2023/20243.725 179 203 239 292 496 314 342 569 150 204 298 439
2024/20259.842 357 209 270 727 1.882 1.501 628 693 967 583 772 1.253
2025/202619.262 1.211 601 1.616 1.833 2.728 1.255 2.462 1.043 1.812 1.947 1.506 1.248
2026/20275.747 681 1.207 1.462 2.166 231 0 0 0 0 0 0 0
Totale 60.697